PDCD1 and neoplasm: Patients with TNBC are more likely to benefit from anti-PD-L1/PD1 therapy than those with other BRCA subtypes because of higher immunogenicity, increased enrichment of tumor-infiltrating lymphocytes (TILs), and higher levels of PD-L1 expression (10, 45–47).